profit from every $100 of sales.
$0$100
Fate Therapeutics
$1.28-4.48% today
+29.0% in 1 year
1-year low $0.961-year high $3.11
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Fate Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $96.3 million in 2022 to $6.65 million in 2025, with -$136 million of profit last year.
SalesProfit
Fate Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Fate Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Fate Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 96 | 64 | 14 | 7 | |
| – | – | – | – | |
| -308 | -191 | -196 | -148 | |
| -295 | -172 | -177 | -135 | |
| -282 | -161 | -186 | -136 | |
| -2.91 | -1.64 | -1.64 | -1.15 | |
| – | – | – | – | |
| -320.2% | -299.9% | -1,434.5% | -2,222.4% | |
| -292.5% | -253.3% | -1,366.5% | -2,051.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 706 | 506 | 441 | 319 |
| Cash | 61 | 42 | 36 | 47 |
| Total debt | 109 | 104 | 85 | 78 |
| Total liabilities | 222 | 138 | 122 | 112 |
| 484 | 368 | 319 | 207 | |
| 97 | 98 | 114 | 119 | |
| -41.1% | -31.9% | -38.2% | -40.9% | |
| -58.2% | -43.7% | -58.4% | -65.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -248 | -132 | -123 | -106 | |
| 36 | 6 | 1 | 6 | |
| -284 | -138 | -124 | -112 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 79 | 43 | 41 | 25 |
Valuation
- –
- –
- –
- 1.4×
- 23.4×
- –
- –
- -72.0%
- -87.6%
- 0.0%
Profitability
- -94.1%
- -2,222.4%
- -2,051.1%
- -2,106.1%
- -51.4%
- -40.4%
- -55.0%
- -42.7%
- -52.2%
- 1,622.5%
Growth
- −59.0%
- –
- +9.4%
- –
- +5.8%
Financial health
- –
- 0.38
- 24.4%
- –
- 5.79
- 5.79
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 946
Bottom 1%of 867
Bottom 1%of 986
What analysts expect
- Average price target
- $39.50
- Range
- $3.00 – $145.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.26 | -0.29 | +10.3% |
| Feb 26, 2026 | -0.27 | -0.27 | +0.0% |
| Nov 13, 2025 | -0.27 | -0.29 | +6.9% |
| Aug 12, 2025 | -0.29 | -0.35 | +17.1% |
| May 13, 2025 | -0.32 | -0.39 | +17.9% |
| Mar 5, 2025 | -0.31 | -0.44 | +29.5% |
| Nov 12, 2024 | -0.40 | -0.42 | +4.8% |
| Aug 13, 2024 | -0.33 | -0.47 | +29.8% |
News
Social Security’s fate — and your benefits — are in the hands of the candidates elected this yearMarketWatch · Oct 31, 20264 Developments That Will Determine the Fate of Lucid and Potential BankruptcyYahoo Finance · Oct 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
59No pass
Philip Fisher
29No pass
Peter Lynch
5No pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
26No pass
Questions about Fate Therapeutics
Is Fate Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Fate Therapeutics AI analysis
What does Fate Therapeutics do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. It is in Biotechnology.
Does Fate Therapeutics pay a dividend?
No. Fate Therapeutics does not pay a dividend at the moment.
Is Fate Therapeutics stock halal?
No. Fate Therapeutics does not pass our halal screen: its debt is 48% of its market value, at or above the 33% limit. How we check
How has Fate Therapeutics stock done over the past year?
Up 29.0% over the past twelve months, to $1.28. It traded between $0.96 and $3.11 and is 58.8% below its high.
Who are Fate Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Fate Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.